SecBot SecBot
SECBOTREPLAY Home › Report › VTGN

VTGN · FDA feedback on fasedienol

Vistagen Therapeutics, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET

Vistagen announced constructive FDA feedback from a Type C meeting on fasedienol for social anxiety disorder, including endorsement of the LSAS as a primary endpoint and guidance on interim assessments. The company plans to submit a revised Phase 3 protocol focusing on the general SAD population. No approval, funding, or timeline was provided, and the company's $7M market cap raises significant financing risk.

  • FDA provided constructive feedback on using LSAS as primary endpoint in a future Phase 3 study for fasedienol in SAD.
  • FDA recommended interim assessments (eDiaries, patient surveys) to evaluate acute and longer-term effects.
  • Vistagen plans to submit a revised protocol focusing on the general SAD population, not just acute treatment.
  • FDA recognized fasedienol's reported safety profile and potential to benefit a broad SAD population.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access